Samsung Biologics · 임원ㆍ주요주주특정증권등소유상황보고서
Report on Specified Securities Owned by Officers and Major Shareholders
6.1
삼성바이오로직스
20261117
Report on Specified Securities Owned by Officers and Major Shareholders
| To: Securities and Futures Commission | ||
| To: Korea Exchange | ||
| Reporting obligation date: | 2026-11-17 | |
| Report reference date: | 2026-11-18 | |
| ※ The reporting person confirms that ownership of specified securities as of the reference date is accurately stated per applicable laws and filing instructions, with no material misstatement or omission. |
| Reporting person: | 존 림 |
| Company Name | Samsung Biologics Co., Ltd. | ||
| Entity type | KOSPI-listed company | Company code | 207940 |
| Total Shares Issued | 48,560,951 | ||
| Report Type | Change | Reporting person type | 개인(외국) | |
| Name (Entity Name) | Korean | 존림 | Chinese characters (English) | Rim JohnChongbo |
| Date of Birth or Business Registration No., etc. | 611016 | |||
| Address (Head Office) [Town/District Level Only] | 서울특별시 서초구 반포동 | |||
| Relationship to Issuer | Officer (Registered or Not) | Registered Officer | Position | CEO |
| Appointment Date | 2018-09-10 | Resignation Date | - | |
| Major Shareholder | - | |||
| Business contact and person in charge | Affiliated company | Samsung Biologics Co., Ltd. | Department | IR Team |
| Position | 프로 | Phone Number | 032-45** | |
| Name | 박준범 | Fax number | 032-45** | |
| Email address | **[email protected] | |||
| Report reference date | Specified Securities | Share Certificates | |||
| Number of Specified Securities (shares) | Ratio (%) | Number of Shares (shares) | Ratio (%) | ||
| Previous Report | 2026-10-26 | 270 | 0.00 | 260 | 0.00 |
| This Report | 2026-11-18 | 272 | 0.00 | 272 | 0.00 |
| Change | 2 | 0.00 | 12 | 0.00 | |
| Details of Specified Securities | |||||||||
| Share certificates | Instruments representing preemptive rights | Convertible bonds | Bonds with warrants | Participating Bonds | Exchangeable bonds | Depositary receipts | Other | Total | |
| Number of shares | Ratio (%) | ||||||||
| 272 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 272 | 0.00 |
| A | B | C | D | E | F | G | H | ||
| I | |||||||||
| Total Shares Issued (J) | Number of Specified Securities Other Than Shares (B+C+D+E+F+G+H=I) | Ownership ratio (%) | |
| Ownership Ratio of Specified Securities [A+I / J+I-(F+G+H)※] × 100 | Shareholding Ratio (A / J) × 100 | ||
| 48,560,951 | 0 | 0.00 | 0.00 |
※ Ownership ratio excludes from the denominator only exchangeable bonds exchangeable into shares and depositary receipts, derivative-linked securities, etc. with shares as underlying
| Reason for Report | Change Date* | Type of Specified Securities | Shares Owned (shares) | Acquisition/Disposal Unit Price (KRW)** | Remarks | Trading plan report date | ||
| Before Change | Change | After Change | ||||||
| 기타(-) | 2026-11-17 | Instruments representing preemptive rights | 10 | -10 | 0 | - | 유상청약에 따른신주인수권 효력 상실 | - |
| 유상신주취득(+) | 2026-11-17 | Common Stock | 260 | 12 | 272 | 1,174,000 | 구주주 청약 | - |
| Total | 270 | 2 | 272 | - | - | |||
* For trades on the securities market, the settlement date
** For securities other than shares, the exercise (conversion/exchange) price of the securities or the unit price of shares acquired/disposed of through exercise of rights; amounts in ( ) are the unit price of the securities